William Blair Raises Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at William Blair upped their Q1 2025 EPS estimates for shares of Krystal Biotech in a research note issued on Wednesday, February 19th. William Blair analyst S. Corwin now expects that the company will earn $1.47 per share for the quarter, up from their previous forecast of $1.25. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.64 EPS, Q3 2025 earnings at $1.82 EPS, Q4 2025 earnings at $2.11 EPS, FY2025 earnings at $7.04 EPS and FY2026 earnings at $9.97 EPS.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.30 EPS.

Several other analysts have also recently weighed in on KRYS. Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday, February 19th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Citigroup upped their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Down 3.1 %

Shares of NASDAQ KRYS opened at $181.10 on Monday. The firm’s 50-day simple moving average is $158.24 and its 200 day simple moving average is $175.31. The company has a market cap of $5.22 billion, a price-to-earnings ratio of 60.57 and a beta of 0.84. Krystal Biotech has a 12-month low of $125.85 and a 12-month high of $219.34.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 14.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds have recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter worth approximately $40,000. Huntington National Bank raised its holdings in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares during the period. Blue Trust Inc. raised its holdings in Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after buying an additional 412 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Krystal Biotech during the 4th quarter worth approximately $95,000. Finally, KBC Group NV raised its holdings in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after buying an additional 132 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).